Information regarding TC +/– ICI for 32 patients.
| Information | n (%) or median (range) |
|---|---|
| Median number of weeks on TC (range) | 12 (3–53) |
| Median number of cycles (range) | 4 (1–14) |
| Dosing every 3 weeks | 26 (81%) |
| Dosing weekly | 6 (19%) |
| Dose reduction of carboplatin required | 4 (13%) |
| Dose reduction of paclitaxel required | 6 (19%) |
| Paclitaxel held/discontinued due to peripheral neuropathy | 6 (19%) |
| ICI added to TC | 26 (81%) |
| Maintenance ICI after TC discontinuation | 9 (28%) |
| Median number of weeks of ICI after starting TC (range) | 16.6 (3–230) |
| Median number of doses of ICI after starting TC (range) | 5.5 (1–74) |
TC: paclitaxel and carboplatin; ICI: immune checkpoint inhibitor.
AJ: Writing—review & editing, Writing—original draft, Visualization, Investigation, Formal analysis, Data curation, Conceptualization. MM: Writing—review & editing, Investigation, Data curation. MS: Writing—review & editing, Investigation. TB: Writing—review & editing, Investigation. AS: Writing—review & editing, Investigation. EIH: Writing—review & editing, Investigation. BAC: Writing—review & editing, Investigation. JJO: Writing—review & editing, Investigation. JFQ: Writing—review & editing, Investigation. DSC: Writing—review & editing, Visualization, Investigation, Formal analysis, Data curation, Conceptualization, Supervision. LCP: Writing—review & editing, Writing—original draft, Visualization, Investigation, Formal analysis, Data curation, Conceptualization, Supervision. All authors read and approved the submitted version.
AJ has received personal fees from RealTimeCase, honoraria from MJH Life Sciences and Curio Science, and travel funds from MECC Inc and the Binaytara Foundation. JJO receives research support from the Prostate Cancer Foundation (YIA), Department of Defense, and National Cancer Institute (K12 CA90628-23), has current clinical trial support from Janux Therapeutics, and has received support from NaNotics, NEXUS Global, Genentech, Johnson & Johnson, and Partner Therapeutics, and reports support and/or research and consulting support from the Prostate Cancer Foundation, NaNotics, Nexus Global, Genentech, and Partner Therapeutics. All other authors report no relevant conflicts of interest.
This study was approved by the Mayo IRB#: 20-011547.
This study was deemed exempt by the Mayo Clinic Institutional Review Board (IRB#: 20-011547), so individual patient consent was not required.
This study was deemed exempt by the Mayo Clinic Institutional Review Board (IRB#: 20-011547), so individual patient consent was not required.
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
Not applicable.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.